Insider Stock Transactions at Aehr Test Systems
Several executives at Aehr Test Systems, including the CEO, reported routine stock transactions on October 27, 2026, related to tax withholding.
Stocks · News reference
Corning, Cellectis, Biodexa Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures fell, with Nasdaq 100 futures down 500 points. Corning dropped 8% after a $2B offering; several other stocks also slid premarket.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Shares of semiconductor and chip companies are trading higher as the sector rebounds from last week's weakness, with CoreWeave, the bellwether, rising on a Goldman Sachs upgrade. The Philadelphia Semiconductor Index is expected to end its longest losing streak since the 2008 financial crisis.
Silence Therapeutics, Disc Medicine, Veradermics And Other Big Stocks Moving Higher On Monday
U.S. stocks mixed as Dow fell ~100 points; Silence Therapeutics surged 125.7% on Merck KGaA buyout, while biotech and tech shares gained.
Shares of semiconductor and chip companies are trading lower as rising inflation concerns and elevated energy prices fuel expectations for further Fed rate hikes. Elevated borrowing costs could pressure semiconductor manufacturing and AI infrastructure investments while straining customer budgets. The Philadelphia Semiconductor Index (SOX) has declined for seven consecutive trading sessions, matching its longest losing streak since the 2008 financial crisis.
Biodexa Pharmaceuticals Announces 1-for-8 Reverse Stock Split
Biodexa Pharmaceuticals has announced a 1-for-8 reverse stock split of its shares, scheduled to take effect on October 26, 2026.
Biodexa Pharmaceuticals shares are trading higher after the company announced it enrolled 100 patients in its registrational Phase 3 trial of eRapa in Familial Adenomatous Polyposis.